Literature DB >> 8845035

Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase.

I J Sørensen1, E H Nielsen, O Andersen, B Danielsen, S E Svehag.   

Abstract

Serum amyloid P component (SAP), a member of the conserved pentraxin family of plasma proteins, binds calcium dependently to its ligands. The authors investigated SAPs interaction with the complement proteins C4b binding protein (C4bp) and C1q by ELISA, immunoelectrophoresis and electron microscopy. Binding of these proteins to SAP was demonstrated when SAP was immobilized using F(ab')2 anti-SAP, but not when SAP reacted with these proteins in liquid phase; thus the binding to human SAP was markedly phase state dependent. Presaturation of solid phase SAP with heparin, which binds SAP with high affinity, did not interfere with the subsequent binding of C4bp or C1q to SAP. In contrast, collagen I and IV showed partial competition with the binding of C1q to SAP. Using fresh serum, immobilized native SAP bound C4bp whereas binding of C1q/C1 could not be demonstrated. Altogether the results indicate that firm binding of C1q and C4bp to SAP requires that SAP is presented on a solid phase, that C1q and C4bp react with sites distinct from the heparin binding site, and that C1q and collagen I share binding sites on SAP. Immobilized native SAP, aggregated SAP and SAP-heparansulphate complexes induced no detectable complement activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8845035     DOI: 10.1046/j.1365-3083.1996.d01-326.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

1.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 2.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

3.  Immunological Aspects of Age-Related Macular Degeneration.

Authors:  Michael J Allingham; Anna Loksztejn; Scott W Cousins; Priyatham S Mettu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Ligation of CD46 to CD40 inhibits CD40 signaling in B cells.

Authors:  Haifa H Jabara; Federica Angelini; Scott R Brodeur; Raif S Geha
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

5.  Complement activation in relation to capillary leakage in children with septic shock and purpura.

Authors:  J A Hazelzet; R de Groot; G van Mierlo; K F Joosten; E van der Voort; A Eerenberg; M H Suur; W C Hop; C E Hack
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

6.  Monocyte differentiation and macrophage priming are regulated differentially by pentraxins and their ligands.

Authors:  Darrell Pilling; Elkin Galvis-Carvajal; Tejas R Karhadkar; Nehemiah Cox; Richard H Gomer
Journal:  BMC Immunol       Date:  2017-06-15       Impact factor: 3.615

7.  T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.

Authors:  Emily K Forbes; Simone C de Cassan; David Llewellyn; Sumi Biswas; Anna L Goodman; Matthew G Cottingham; Carole A Long; Richard J Pleass; Adrian V S Hill; Fergal Hill; Simon J Draper
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

8.  Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae.

Authors:  Jose Yuste; Marina Botto; Stephen E Bottoms; Jeremy S Brown
Journal:  PLoS Pathog       Date:  2007-09-28       Impact factor: 6.823

Review 9.  Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.

Authors:  Jack Mellors; Tom Tipton; Stephanie Longet; Miles Carroll
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

Review 10.  The Development of Serum Amyloid P as a Possible Therapeutic.

Authors:  Darrell Pilling; Richard H Gomer
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.